26.05.2011 • NewsAkzoNobel

AkzoNobel Widens Global Research Center Network

AkzoNobel has opened a new research laboratory in Deventer, the Netherlands, which the company says will play a pivotal role in its ambition to drive future growth through pioneering innovation.

Housing more than 200 top researchers from the company's Research, Development and Innovation (RD&I) organization, the facility is one of a network of six global RD&I centers that work with the company's businesses to undertake the breakthrough research which leads to major innovations.

The six global RD&I Centers host a combination of business-led R&D groups and several of the company's Expert Capability Groups, who work in partnership with AkzoNobel's businesses. Their role is critical in delivering the company's ambition of increasing the contribution made by bigger and bolder innovations from about 9% to between 15 and 20% of revenue by 2015, and ensuring that at least 30% of sales will be derived from eco-premium solutions. In 2010, the company spent close to 20% of its global R&D budget in the Netherlands.  

 

 

Company

Logo:

AkzoNobel

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.